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WOMEN'S HEALTH 
Osteoporosis and ERT-The jury is still out 
As most readers of JAMW A will know, the Public Health Service formed a 
Task Force on Women's Health Issues in 1983. Each agency of the Public 
Health Service now has a Women's Health Coordinating Committee. The 
committee at the Centers for Disease Control has decided to focus on 
publicizing selected women's health issues as well as providing a forum for 
discussion and debate. Although the Task Force issued a two-volume report, 
many of the issues covered in the report have not had the publicity we think 
they deserve. We hope that airing the issues will be a catalyst to action for 
·researchers and public health authorities as well as physicians dedicated to 
patient care. That is why we have initiated this new column in JAMW A. 
Our first topic, osteoporosis, has received much media attention, perhaps 
too much, especially in women's magazines. But there are still some 
questions-about the wisdom of estrogen replacement therapy, for exam-
ple-that deserve closer consideration and further research. This report is 
based on an NIH-sponsored workshop, "Research Directions in Osteoporo-
sis," held February 9-11, 1987, and a critical review of the data by 
Barrett-Connor. 
-CDC Women's Health Coordinating Committee 
Mary E. Guinan, MD, PhD; Karen Steinberg, PhD; Lambertina 
Freni-Titulaer, MD, MSPH 
Bone loss in women accelerates 
immediately after menopause, often 
leading to osteoporosis and an 
increased risk of bone fractures. In 
1985,247,000 hip fractures occurred 
in people over 45 years of age. 
Among those who live to be 90, 
one-third of women and one-sixth of 
men will experience hip fractures. 
Six months after fracture, 25% of 
victims will not be able to carry out 
their usual activities, and 50% will 
need assistance to do so. Hip frac-
tures are not only a serious cause of 
morbidity but they also increase the 
risk of mortality in older people. 
Because the proportion of the popu-
lation over 65 will increase steadily, 
from 11% in 1981 to 22% in 2050, 
the estimated number of hip frac-
tures will triple by the year 2050. 
Established risk factors for osteo-
porosis include being thin, white, and 
female. Alcohol consumption, ciga-
rette smoking, and low dietary calci-
um may also increase risk. Estrogen 
use retards postmenopausal bone loss 
and reduces the risk of osteoporosis. 
The risk of hip fracture is considera-
bly reduced in women who use post-
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menopausal estrogens. For maxi-
mum effect, estrogen should be 
started as soon as possible after 
menopause. The suggested dose is 
0.625 mg, but the optimal duration 
of use is unknown. Experts suggest a 
minimum of five to ten years. 
Should all women be aavised to 
take postmenopausal estrogens? It 
has been estimated that at present 
approximately 40 million women in 
the United States are functionally 
postmenopausal, but only about 4 to 
5 million of them are taking estro-
gen. Other factors besides the benefi-
cial effect on osteoporosis must be 
taken into consideration before 
deciding on the use of postmenopaus-
al estrogen. 
In a recent review, Barrett-Con-
nor1 stated that postmenopausal 
estrogen replacement was associated 
with an established increased risk of 
endometrial cancer and a possibly 
increased risk of breast cancer and 
an established decreased risk of both 
osteoporosis and cardiovascular dis-
ease. She emphasized that almost all 
risk data available were based on 
estrogen therapy with conjugated 
equine estrogen (Premarin*) given in 
doses ranging from 0.625 mg to 1.25 
mg without a progestin. It cannot be 
assumed that other estrogen prepara-
tions have the same risks and bene-
fits. Nor can it be assumed that 
estrogens given with progestins will 
have the same effects. 
Multiple case control studies have 
found an association between endo-
metrial cancer and estrogen replace-
ment therapy with the risk generally 
increasing with dose and duration of 
use. The American College of 
Obstetrics and Gynecology has rec-
ommended that estrogen replace-
ment therapy include a progestin to 
reduce endometrial cancer. Although 
biologically plausible, not enough 
data exist to definitely state that the 
addition of a progestin will mitigate 
the increased risk of endometrial 
cancer associated with estrogen 
replacement. And even more worri-
some are the possible adverse effects 
of added progestins on breast cancer 
and cardiovascular disease. 
Exogenous estrogen use has not 
been associated with breast cancer in 
most studies; however, long-term fol-
low-up is necessary to exclude risk. 
The addition of progestin to estrogen 
replacement has not been studied 
sufficiently to determine its effect on 
breast cancer, although one study 
suggests that estrogen-progestin 
therapy was protective against breast 
cancer compared to estrogen alone or 
no estrogen.2 
For women over age 65 in the 
United States, the death rate from 
myocardial infarction increases dra-
matically each year, and it greatly 
exceeds rates for both breast and 
endometrial cancer. If postmeno-
pausal estrogen therapy had a benefi-
*Trade names are used for identification 
purposes and do not constitute endorse-
ment by the Centers for Disease Control 
or the U. S. Public Health Service. 
cial effect on cardiovascular risk, a 
stronger case might be made for its 
use in the prevention of ischemic 
heart disease than in the prevention 
of osteoporosis. However, the data on 
estrogen use and risk of heart disease 
are conflicting. In two studies pub-
lished together in 1985, one showed 
an increased risk and the other 
showed a decreased risk of coronary 
artery disease associated with exoge-
nous estrogen use. 3•4 The weight of 
the evidence at present, however, 
suggests that postmenopausal estro-
gen use decreases the risk of cardio-
vascular disease. Barrett-Connor1 
points out that a progestin supple-
ment may reverse the potential car-
diovascular benefit of estrogen use 
by blocking the estrogen-induced 
increase in high density lipoprotein 
cholesterol. 
One side effect of estrogen 
replacement therapy is vaginal bleed-
ing. This may lead to an increase in 
diagnostic dilation and curettage 
procedures and to an increased rate 
of hysterectomy. If progestins are 
added, menstrual periods will likely 
ensue. Many women may refuse 
estrogen-progestin replacement ther-
apy because they do not want to 
continue menstruating after meno-
pause. In fact, very little information 
is available on how women decide 
whether or not to take estrogen 
replacement at the time of meno-
pause. Another side effect of estro-
gen replacement therapy is an 
increase in gall bladder disease. 
One interesting new area is the use 
of transdermal estradiol. Preliminary 
evidence suggests that estrogen taken 
by nonoral routes may be effective 
against osteoporosis and have fewer 
side effects than oral estrogens. 
However, transdermal patch estradi-
ol has not yet been studied in well-
controlled trials. 
As this summary suggests, many 
questions exist concerning the use of 
postmenopausal estrogens. The deci-
sion to prescribe estrogen must be 
made after considering the risks and 
benefits to the individual patient. 
Women receiving estrogen should be 
examined frequently for complica-
tions, especially vaginal bleeding. 
Frequent breast examinations and 
annual mammography are also 
advised. 
Dr. Guinan is Acting Assistant Director 
for Science at the CDC. Dr. Steinberg is 
a research microbiologist and Dr. Freni-
Titulaer a medical epidemiologist, both 
of whom are studying osteoporosis. 
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